CURRENTLY AVAILABLE TREATMENT OPTIONS FOR METASTATIC RENAL CELL CARCINOMA
B. Ya. Alekseev,
A. D. Kaprin,
G. P. Kolesnikov,
A. A. Mukhomed’yarova,
E. I. Konopleva,
A. S. Kalpinskiy https://doi.org/10.17650/1726-9776-2018-14-3-25-36
Abstract
Over the last 10 years, the capacities of second-line systemic therapy for metastatic renal cell carcinoma (mRCC) changed significantly. Targeted therapy is a standard treatment for patients with mRCC. However, the choice of therapeutic agents for such patients remains challenging. In the absence of reliable prognostic biomarkers, physicians can use only the results of randomized clinical trials and their own routine experience with targeted drugs when choosing a regimen of second-line therapy. The article discusses the current situation with second-line therapy with the three new options available for patients with mRCC. It also contains a case report, describing our successful experience of treatment a female patient that received 6 variants of chemotherapy with good effect during 89 months after the diagnosis.
Keywords
renal cancer,
lenvatinib,
metastatic renal cell carcinoma,
targeted therapy,
tyrosine kinase inhibitor
Supporting agencies: Eisai Co., Ltd.
About the Authors
B. Ya. Alekseev
N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
Build. 4, 51 3rd Parkovaya St., Moscow 105425.
Competing Interests: No conflict of interest.
A. D. Kaprin
N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
Build. 4, 51 3rd Parkovaya St., Moscow 105425.
Competing Interests: No conflict of interest.
G. P. Kolesnikov
Moscow City Oncology Hospital No. 62, Moscow Healthcare Department
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
6 Staropetrovskiy Proezd, Moscow 125130.
Competing Interests: No conflict of interest.
A. A. Mukhomed’yarova
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
E. I. Konopleva
M.V. Lomonosov Moscow State University
Russian Federation
1 Leninskie Gory, Moscow 119991.
Competing Interests: No conflict of interest.
Russian Federation
1 Leninskie Gory, Moscow 119991.
Competing Interests: No conflict of interest.
A. S. Kalpinskiy
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
References
1. International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
2. Malignant tumors in Russia in 2014 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 250 p. (In Russ.).
3. Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on renal cell carcinoma. Available at: http://uroweb.org/guideline/renal-cell-carcinoma/.
4. National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer. V.4.2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf April 23, 2018.
5. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5): 58–68. DOI: 10.1093/annonc/mdw328. PMID: 27664262.
6. Clinical guidelines for the treatment of cancer of the renal parenchyma in adults, Ministry of Health of the Russian Federation, 2017. Available at: http://cr.rosminzdrav.ru/#!/schema/87. (In Russ.).
7. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI: 10.1056/NEJ-Moa065044. PMID: 17215529.
8. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI: 10.1200/JCO.2009.23.9764. PMID: 20100962.
9. Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11. DOI: 10.1016/S0140-6736(07)61904-7. PMID: 18156031.
10. Rini B.I., Halabi S., Rosenberg J.E. at al. Phase III trial bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI: 10.1200/JCO.2009.26.5561. PMID: 20368558.
11. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90. DOI: 10.1200/JCO.2008.20.1293. PMID: 19487381.
12. Escudier B., Bellmunt J., Negrier S. et al. Phase III trial bevacizumab plus interferon alfa in patients with metastatic renal cell carcinoma (AVOREN): final results of overall survival. J Clin Oncol 2010;28(13):2144–50. DOI: 10.1200/JCO.2009.26.7849. PMID: 20368553.
13. Sternberg C.N., Hawkins R.E., Wagstaff J. et al. A randomized, double-blind, phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287–96. DOI: 10.1016/j.ejca.2012.12.010. PMID: 23321547.
14. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.
15. Negrier S. Temsirolimus in metastatic renal cell carcinoma. Ann Onc 2008;19(8): 1369–70.
16. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449–56. DOI: 10.1016/S0140-6736(08)61039-9. PMID: 18653228.
17. Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931–9. DOI: 10.1016/S0140-6736(11)61613-9. PMID: 22056247.
18. Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI: 10.1056/NEJ-Moa1510665. PMID: 26406148.
19. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1814–23. DOI: 10.1056/NEJ-Moa1510016. PMID: 26406150.
20. Medication package insert for Lenvima. RU No. LP 003398. Registration date 29.12.2015 (amended 06.12.2016). (In Russ.).
21. Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI: 10.1016/S1470-2045(15)00290-9. PMID: 26482279.
22. Motzer R.J., Hutson T.E., Ren M. et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17(1):e4–5. DOI: 10.1016/S1470-2045(15)00543-4. PMID: 26758760.
23. Grande E., Martínez-Sáez O., Gajate-Borau P., Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017;8(2):100–5. DOI: 10.5306/wjco.v8. i2.100. PMID: 28439491.
Review
For citations:
Alekseev B.Ya., Kaprin A.D., Kolesnikov G.P., Mukhomed’yarova A.A., Konopleva E.I., Kalpinskiy A.S. CURRENTLY AVAILABLE TREATMENT OPTIONS FOR METASTATIC RENAL CELL CARCINOMA. Cancer Urology. 2018;14(3):25-36. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-3-25-36
Views:
852
Email this article 